Won’t there be a single drug against COVID-19? “It should be a miracle drug, cured as if by touching a stick,” – said the professor. Krzysztof Tomasiewicz. According to the expert, making a single drug against the disease caused by the SARS-CoV-2 coronavirus is impossible, because the disease has many faces and proceeds in several stages.
COVID-19 is a very complex disease, and specialists have divided its course into four stages. Research is underway around the world to develop drugs that treat different stages of the disease.
a. There is no universal drug for COVID-19, because it is a very complex disease and each of the four stages are different, and therefore require a different reaction, Krzysztof Tomasiewicz, Head of the Department and Clinic of Infectious Diseases at Lublin Medical University, said in an interview with the Polish news agency.
There will be no universal medicine against COVID-19
What is the medicine for covid? Is it a drug that is supposed to inhibit the development of the disease at an early stage? Is it a medicine to heal the dying? Professor Dr. said. Tomasiewicz, a member of the COVID-19 Medical Council working under the Prime Minister’s Office and Vice President of the Polish Association of Epidemiologists and Infectious Diseases Physicians.
In an interview with PAP, the professor mentioned that COVID-19 is a very complex disease, the course of which has been divided by specialists into four stages. Research is underway around the world to develop drugs that treat different stages of the disease.
He also stressed the importance of the time in which the patient informs the doctor after the appearance of the first symptoms of the disease.
People progress at different stages and need interventions at different stages. Even if a miracle antiviral drug is created, if the patient informs the doctor in the last stage — the third or fourth — that drug will not help him at all — Tomasiewicz said and invoked the textbook principle of the drug’s action, known as an ‘antiviral’.
– It should be used as soon as virus infection is detected, at the onset of symptoms, but before the virus multiplies rapidly and the possible development of the uncontrolled inflammatory reaction known as a ‘cytokine storm’.
“It must be a miracle drug, that heals as if at the touch of a stick”
In recent weeks, the media has reported more drugs that have successfully passed phase 3 clinical trials and are positively recommended by international medical institutions. In August this year. The British Medicines Regulatory Authority has approved the drug Ronapreve, which uses antibodies created in a laboratory to fight the Corona virus. This medication is used to treat and prevent SARS-CoV-2 infection in patients over 12 years of age who are at risk of developing a serious condition. “This means that it must be applied very early,” – the expert noted.
a. Krzysztof Tomasiewicz is leading a clinical trial using a specific immunoglobulin – an antibody produced by the human body, taken from the plasma of convalescents. The preparation for the treatment of COVID-19 was developed by Biomed in Lublin, and the clinical trial, which began at the beginning of the year and included 100 patients, was funded by the State Medical Research Agency.
The medicine used by A. Tomasiewicz is intended for patients classified as stage I and II – that is, before the onset of inflammation in the body.
– We recruited 100 patients – the last of whom had just finished treatment. This is a randomized, double-blind trial – just as it should be for this type of trial. Our statisticians are beginning to unblind patients and by the end of September we will be able to tell you the benefits of using IgM. We are already after the evaluation of the independent safety committee and this evaluation is very positive – there are no serious side effects – the professor reported. Tomasiewicz during an online lecture organized on Wednesday 25 August by the Polish Academy of Sciences and the Copernicus Science Center.
The expert also explained the difficulty of the clinical trial. The patient is given a variety of medications, and a few are turned on or off with the experimental drug. In the end, it is very difficult to assess what ultimately affected the patient’s condition and not another.
After all, these patients – regardless of whether they take plasma, placebo or immunoglobulin – are saved with other drugs – such as giving oxygen, steroids, remdesivir, etc. It is not easy to point out a single differentiation factor. It must be a miracle drug, as if to heal with the touch of a wand – to show the differences between the two groups in an immediate and clear way – concluded the specialist.
Source: PAP / Urszula Kaczorowska
“Internet Geek. Food Enthusiast. Thinker. Beer Practitioner. Bacon Specialist. Music Addict. Traveler.”